Annual Meeting

New insights into an old drug: Scientists discover why aspirin works so well

Understanding how aspirin reduces inflammation could lead to alternatives with fewer side effects
Nancy D. Lamontagne
March 28, 2023

New research has revealed important information about how aspirin works. Even though this drug has been available commercially since the late 1800s, scientists have not yet fully elucidated its detailed mechanism of action and cellular targets. The new findings could pave the way to safer aspirin alternatives and might also have implications for improving cancer immunotherapies.

Aspirin, which is a nonsteroidal anti-inflammatory drug, is one of the most widely used medications in the world. It is used to treat pain, fever and inflammation, and an estimated 29 million people in the U.S. take it daily to reduce the risk of cardiovascular diseases.

Researchers have made new discoveries about aspirin’s mechanism of action and cellular targets. Their findings suggest potential interplay between cyclooxygenase enzyme, or COX, and indoleamine dioxygenases, or IDOs, during inflammation.
Subhrangsu Mandal, University of Texas at Arlington
Researchers have made new discoveries about aspirin’s mechanism of action and cellular targets. Their findings suggest potential interplay between cyclooxygenase enzyme, or COX, and indoleamine dioxygenases, or IDOs, during inflammation.

Scientists know that aspirin inhibits the cyclooxygenase enzyme, or COX, which creates messenger molecules that are crucial in the inflammatory response. Researchers led by Subhrangsu Mandal, a professor of chemistry and biochemistry at the University of Texas at Arlington, have discovered more about this process.

Prarthana Guha, a graduate student in Mandal’s lab, will present the team’s findings at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, March 25–28 in Seattle. Avisankar Chini also made significant contributions to the study.

“Aspirin is a magic drug, but long-term use of it can cause detrimental side effects such as internal bleeding and organ damage,” Mandal said. “It’s important that we understand how it works so we can develop safer drugs with fewer side effects.”

The team found that aspirin controls transcription factors required for cytokine expression during inflammation while also influencing many other inflammatory proteins and noncoding RNAs that are critically linked to inflammation and immune response. Mandal said this work has required a unique interdisciplinary team with expertise in inflammation signaling biology and organic chemistry.

They also showed that aspirin slows the breakdown of the amino acid tryptophan into its metabolite kynurenine by inhibiting associated enzymes called indoleamine dioxygenases, or IDOs. Tryptophan metabolism plays a central role in the inflammation and immune response.

“We found that aspirin downregulates IDO1 expression and associated kynurenine production during inflammation,” Mandal said. “Since aspirin is a COX inhibitor, this suggests potential interplay between COX and IDO1 during inflammation.”

IDO1 is an important target for immunotherapy, a type of cancer treatment that helps the body’s immune system seek out and destroy cancer cells. Because COX inhibitors modulate the COX–IDO1 axis during inflammation, the researchers predict that COX inhibitors might also be useful as drugs for immunotherapy.

Mandal and his team are now creating a series of small molecules that modulate COX–IDO1 and will explore their potential use as anti-inflammatory drugs and immunotherapeutic agents.

Prarthana Guha will present this research from 4–5:30 p.m. PDT on Tuesday, March 28, in Exhibit Hall 4AB of the Seattle Convention Center (Poster Board No. 185) (abstract). Contact the media team for more information or to obtain a free press pass to attend the meeting.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Nancy D. Lamontagne

Nancy D. Lamontagne is a science writer and editor at Creative Science Writing based in Chapel Hill, North Carolina.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

FDA approves CRISPR–Cas9 therapy for sickle cell disease
News

FDA approves CRISPR–Cas9 therapy for sickle cell disease

Dec. 8, 2023

The gene editing treatment from Vertex Pharmaceuticals and CRISPR Therapeutics is the first of its kind

From the journals: MCP
Journal News

From the journals: MCP

Dec. 8, 2023

Metals contaminate protein samples. Lipid droplets go haywire in Huntington’s. Nerve cells respond to stimulation. Read about these recent papers.

The perfect storm
Feature

The perfect storm

Dec. 6, 2023

The world has 2023 Nobel laureates Katalin Karikó, Drew Weissman and others to thank for laying a foundation for the COVID-19 vaccine decades before the pandemic.

Throw your hat in the ring!
Annual Meeting

Throw your hat in the ring!

Dec. 6, 2023

Apply to speak at Discover BMB in Chicago in 2025.

How bacteria inhibit gene expression
Journal News

How bacteria inhibit gene expression

Dec. 5, 2023

Researchers show how altering activity of the transcription factor CarD can cause downregulation and upregulation of some genes.

Where the heck did all those structures inside complex cells come from?
Feature

Where the heck did all those structures inside complex cells come from?

Dec. 3, 2023

Scientists agree that eons ago, a bacterium took up residence inside another cell and became its powerhouse, the mitochondrion. But there are competing theories about the birth of other organelles such as the nucleus and endoplasmic reticulum.